About Us

bonus 1a

Bonus Biogroup (TASE: BONS) is a clinical-stage Israeli biotechnology company active in tissue regeneration and developing biotechnological products based on tissue engineering and cell therapy, with two lead products, BonoFill  and MesenCure, targeting multi-billion-dollar markets.

Our Vision

Bonus BioGroup strives to become a global leader in Next-Generation Therapies in cell therapy and tissue engineering to improve human health

Image

Our mission

Our mission is to help millions of people to live a better and longer life by merging innovative biological sciences and biomedical and biotechnology engineering.

2022

Planned launch of MesenCure global phase III trial and BonoFill™ phase II/III clinical trial in the US

2022

2021

Completed a successful multi-center phase II clinical trial for treating severe COVID patients with MesenCure.

2020

Launch of Phase I/II clinical trial testing MesenCure, an enhanced cell therapy, in severe COVID patients.

2020

2019

Granting Bonus BioGroup’s primary patents for the generation and usage of 3D cell-based bone implants.

2017

Launch of phase I/II clinical trial evaluating the safety and efficacy of BonoFill™ in orthopedic indications.

2017

2016

Successful first-in-human demonstration of the safety and efficacy of BonoFill™ and launch of phase I/II clinical trial testing 2nd generation BonoFill™ for maxillofacial bone regeneration.

2014

Launch of the first-in-human clinical trial with BonoFill™, an injectable bone graft for maxillofacial bone regeneration

2014

2013

Establishment of the world’s first live human bone graft manufacturing facility in Haifa, Israel

2008

Bonus* was founded by experts in tissue engineering and cell therapy led by Dr. Shai Meretzki, who pioneered the industrial development of mesenchymal cell therapies. <read more> *Bonus Therapeutics Ltd., a wholly-owned subsidiary of Bonus BioGroup Ltd.

2008

Bonus Biogroup (TASE: BONS) is a clinical-stage Israeli biotechnology company active in tissue regeneration and developing biotechnological products based on tissue engineering and cell therapy, with two lead products, BonoFill  and MesenCure, targeting multi-billion-dollar markets.

Our Vision

Bonus BioGroup strives to become a global leader in Next-Generation Therapies in cell therapy and tissue engineering to improve human health

Image

Our mission

Our mission is to help millions of people to live a better and longer life by merging innovative biological sciences and biomedical and biotechnology engineering.

2022

Planned launch of MesenCure global phase III trial and BonoFill™ phase II/III clinical trial in the US

2022

2021

Completed a successful multi-center phase II clinical trial for treating severe COVID patients with MesenCure.

2020

Launch of Phase I/II clinical trial testing MesenCure, an enhanced cell therapy, in severe COVID patients.

2020

2019

Granting Bonus BioGroup’s primary patents for the generation and usage of 3D cell-based bone implants.

2017

Launch of phase I/II clinical trial evaluating the safety and efficacy of BonoFill™ in orthopedic indications.

2017

2016

Successful first-in-human demonstration of the safety and efficacy of BonoFill™ and launch of phase I/II clinical trial testing 2nd generation BonoFill™ for maxillofacial bone regeneration.

2014

Launch of the first-in-human clinical trial with BonoFill™, an injectable bone graft for maxillofacial bone regeneration

2014

2013

Establishment of the world’s first live human bone graft manufacturing facility in Haifa, Israel

2008

Bonus* was founded by experts in tissue engineering and cell therapy led by Dr. Shai Meretzki, who pioneered the industrial development of mesenchymal cell therapies. <read more> *Bonus Therapeutics Ltd., a wholly-owned subsidiary of Bonus BioGroup Ltd.

2008

INFORMATION FOR INVESTORS  |  CAREER OPPORTUNITIES  |  INFORMATION FOR PATIENTS   |   RESEARCH COLLABORATIONS & BUSINESS DEVELOPMENT INQUIRIES

INFORMATION FOR INVESTORS

CAREER OPPORTUNITIES

INFORMATION FOR PATIENTS

RESEARCH COLLABORATIONS & BUSINESS DEVELOPMENT INQUIRIES

BONUS BIOGROUP LTD.

Terms of Use | Privacy Policy

MAIL ICON  info@bonus-bio.com

MAIL ICON  +972 (0)73 206 7104

MAIL ICONMatam Advanced Technology
Park P.O.B 15143 Haifa 31905 Israel

you tube linkedin facebook twitter

© 2022 Bonus BioGroup Ltd. Created By Netron Israel Ltd

Login Form